HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Martin Enge Selected Research

NK Cell Lectin-Like Receptor Subfamily K

10/2011Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Martin Enge Research Topics

Disease

7Neoplasms (Cancer)
07/2015 - 12/2004
2Colorectal Neoplasms (Colorectal Cancer)
07/2015 - 02/2015
1Essential Thrombocythemia
12/2021
1Demyelinating Diseases (Demyelinating Disease)
10/2021
1Genomic Instability
07/2015
1Seizures (Absence Seizure)
06/2015
1Melanoma (Melanoma, Malignant)
08/2012
1Leiomyoma (Uterine Fibroids)
10/2011
1Carcinogenesis
07/2010
1Oncogene Addiction
05/2009

Drug/Important Bio-Agent (IBA)

2RNA (Ribonucleic Acid)IBA
12/2021 - 10/2021
2ChromatinIBA
07/2015 - 02/2015
2DNA (Deoxyribonucleic Acid)IBA
07/2015 - 07/2010
2Transcription Factors (Transcription Factor)IBA
12/2011 - 07/2010
1CCCTC-Binding FactorIBA
07/2015
1CohesinsIBA
07/2015
1ElementsIBA
12/2012
1IntegrinsIBA
08/2012
1CollagenIBA
08/2012
1Protein Kinase CIBA
08/2012
1Protein Kinases (Protein Kinase)IBA
08/2012
1EnzymesIBA
12/2011
1Adenosine Triphosphate (ATP)IBA
12/2011
1Mediator ComplexIBA
10/2011
1LigandsIBA
10/2011
1NK Cell Lectin-Like Receptor Subfamily KIBA
10/2011
14,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA
07/2010
1NSC 652287IBA
12/2004
1Pharmaceutical PreparationsIBA
12/2004

Therapy/Procedure

3Therapeutics
12/2011 - 05/2009
1Operative Surgical Procedures
06/2015